1,882 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by Symmetry Partners LLC

Symmetry Partners LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM – Get Rating) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,882 shares of the medical device company’s stock, valued at approximately $213,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in DXCM. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of DexCom by 31.9% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 270,999 shares of the medical device company’s stock worth $138,643,000 after buying an additional 65,516 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of DexCom by 3,596.7% in the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,109 shares of the medical device company’s stock worth $567,000 after buying an additional 1,079 shares during the last quarter. West Family Investments Inc. purchased a new position in shares of DexCom in the first quarter worth approximately $209,000. Ergoteles LLC boosted its holdings in shares of DexCom by 60.6% in the first quarter. Ergoteles LLC now owns 1,681 shares of the medical device company’s stock worth $860,000 after buying an additional 634 shares during the last quarter. Finally, Mackenzie Financial Corp lifted its holdings in DexCom by 26.4% during the first quarter. Mackenzie Financial Corp now owns 29,516 shares of the medical device company’s stock valued at $15,100,000 after purchasing an additional 6,160 shares in the last quarter. Hedge funds and other institutional investors own 94.01% of the company’s stock.

DexCom Trading Down 0.5 %

Shares of DXCM opened at $113.93 on Friday. The company’s fifty day moving average is $111.05 and its 200 day moving average is $106.50. DexCom, Inc. has a fifty-two week low of $66.89 and a fifty-two week high of $134.76. The stock has a market capitalization of $44.02 billion, a PE ratio of 140.22, a P/E/G ratio of 2.76 and a beta of 1.10. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.83 and a current ratio of 1.99.

DexCom (NASDAQ:DXCM – Get Rating) last announced its quarterly earnings results on Thursday, February 9th. The medical device company reported $0.34 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.08. DexCom had a net margin of 11.73% and a return on equity of 16.66%. The company had revenue of $815.20 million for the quarter, compared to analysts’ expectations of $814.52 million. During the same quarter in the previous year, the business posted $0.17 earnings per share. DexCom’s quarterly revenue was up 16.8% on a year-over-year basis. Sell-side analysts expect that DexCom, Inc. will post 1.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In other DexCom news, EVP Barry J. Regan sold 2,213 shares of the business’s stock in a transaction on Monday, January 30th. The shares were sold at an average price of $106.12, for a total transaction of $234,843.56. Following the transaction, the executive vice president now owns 59,386 shares in the company, valued at $6,302,042.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other DexCom news, EVP Barry J. Regan sold 2,213 shares of the business’s stock in a transaction on Monday, January 30th. The shares were sold at an average price of $106.12, for a total transaction of $234,843.56. Following the transaction, the executive vice president now owns 59,386 shares in the company, valued at $6,302,042.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Kevin R. Sayer sold 45,607 shares of the business’s stock in a transaction on Friday, January 20th. The shares were sold at an average price of $105.75, for a total transaction of $4,822,940.25. Following the transaction, the chief executive officer now owns 426,645 shares in the company, valued at approximately $45,117,708.75. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 175,676 shares of company stock worth $18,980,316. Insiders own 0.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on DXCM. Barclays lifted their price target on shares of DexCom from $103.00 to $110.00 and gave the company an “equal weight” rating in a report on Monday, February 13th. Morgan Stanley lifted their price target on shares of DexCom from $117.00 to $131.00 and gave the company an “equal weight” rating in a report on Friday, January 6th. Stifel Nicolaus lifted their price target on shares of DexCom from $120.00 to $130.00 in a report on Tuesday, December 20th. Cowen lifted their price target on shares of DexCom from $114.00 to $125.00 and gave the company an “outperform” rating in a report on Friday, February 10th. Finally, Wolfe Research began coverage on shares of DexCom in a report on Thursday, January 26th. They set an “outperform” rating and a $121.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $123.00.

DexCom Company Profile

(Get Rating)

DexCom, Inc is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F.